Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brimapitide
- Development stage
- Phase 3
- Lead developer
- Altamira Therapeutics
- Modality
- Peptides
- Administration
- Intratympanic
01
Overview
Brimapitide (AM-111) is a synthetic, cell-permeable peptide inhibitor of c-Jun N-terminal kinase (JNK). Developed by Auris Medical (now Altamira Therapeutics), it was designed to protect the delicate sensory cells of the inner ear from stress-induced apoptosis following acute injury, such as sudden sensorineural hearing loss (SSNHL) or acoustic trauma. The drug is administered via a single intratympanic injection of a biocompatible gel, allowing for local delivery to the cochlea and sustained exposure. Despite showing promise in Phase 2 trials, the Phase 3 HEAL trial did not meet its primary efficacy endpoint in the overall study population, leading to the termination of its development for this indication.
- Brand names
- Sonsuvi
- Other names
- D-retro-inverso-c-Jun N-terminal kinase inhibitor 1
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)
Beyond the preview
Go deeper on brimapitide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brimapitide.